Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease

International Urology and Nephrology

Volumn 43, Issue 2, 2011, Pages 565-569

  Peces, Ramón ^a   Cuesta López, Emilio ^a   Peces, Carlos ^b   Pérez Dueñas, Virginia ^a   Vega Cabrera, Cristina ^a   Selgas, Rafael ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b SESCAM   (Spain)

Author keywords

ADPKD; cAMP; Fibrocystic disease of breast; Octreotide; Renal function; Volume change

Indexed keywords

ATENOLOL; OCTREOTIDE; TELMISARTAN;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; CYST FLUID; FEMALE; FIBROCYSTIC BREAST DISEASE; HEPATOMEGALY; HUMAN; HYPERTENSION; KIDNEY CYST; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; LIVER WEIGHT; NAUSEA; PHYSICAL EXAMINATION; TREATMENT DURATION;

ADULT; BREAST CYST; CYSTS; FEMALE; HUMANS; KIDNEY DISEASES, CYSTIC; LIVER DISEASES; OCTREOTIDE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 79959749911     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-010-9748-1     Document Type: Article

References (14)

1. Maleki D, Ghafari A (2009) Cystic changes of breast in a family with autosomal dominant polycystic kidney disease. Iran J Kidney Dis 3:246-248
2. Vargas HI, Vargas MP, Gonzalez KD, Eldrageely K, Khalkhali I (2004) Outcomes of sonography-based management of breast cysts. Am J Surg 188:443-447 (Pubitemid 39330556)
3. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF (2007) Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 30,50-cyclic monophosphate. Gastroenterology 132:1104-1116 (Pubitemid 46440866)
4. Ruggenenti P, Remuzzi A, Ondei P et al (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal- dominant polycystic kidney disease. Kidney Int 68:206-216 (Pubitemid 43181378)
5. van Keimpema LV, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP (2009) Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137:1661-1668
6. Grantham JJ, Torres VE, Chapman AB, CRISP Investigators et al (2006) Volume progression in polycystic kidney disease. N Engl J Med 354:2122-2130 (Pubitemid 43736612)
7. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP, Serra AL (2009) Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75:235-241
8. van Keimpema L, de Man RA, Drenth JP (2008) Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 57:1338-1339
9. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334:246-254 (Pubitemid 26030676)
10. Peces R, Peces C, Pérez-Dueñas V, Cuesta-López E, Azorín S, Selgas R (2009) Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease. Nephrol Dial Transpl PLUS 2:133-135
11. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE (2008) Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19:631-638 (Pubitemid 351355407)
12. AUl Haque, Moatasim A (2008) Adult polycystic kidney disease: a disorder of connective tissue? Int J Clin Exp Pathol 1:84-90
13. Olteanu D, Hovater MB, Schwiebert EM (2007) Intraluminal autocrine purinergic signaling within cysts: implications for the progression of diseases that involve encapsulated cyst formation. Am J Physiol Renal Physiol 292:F11-F14 (Pubitemid 46105238)
14. Hurley DK, Bandy SM, Glew RH, Morris DM, Gardner KD Jr (1997) Kidney and breast cysts: a comparative study of fluids. Nephron 77:304-308 (Pubitemid 27477688)